SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRPs continued pullback and struggle to hold support dominate the discussion, with traders pointing to technical selling and broader crypto weakness. Sentiment is divided between dip buyers and skeptics who argue that Ripples announcements and growing adoption have not translated into sustained XRP demand, citing concerns about token supply and utility.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Attention centers on Compass Pathways anticipated completion of its rolling FDA application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and the prospect of an accelerated review. Many traders see the filing and potential approval as near-term catalysts, while others are frustrated by the lack of a firm submission date and point to biotech-sector weakness and market volatility behind the share-price decline.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyxs approvals of FAYUVI for Sanfilippo syndrome Type A and GENGLYCOS, along with sales of the resulting priority review vouchers, are driving discussion about new gene-therapy launches and non-dilutive funding. Bulls see these developments strengthening the companys path to profitability, while skeptics point to the muted share-price response, execution and cost-cutting needs, and the overhang from a prior trial setback.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention is centered on CRISPR Therapeutics upcoming CTX310 Phase 1b data at the AHA meeting, with traders viewing the in-vivo gene-editing readout as a key catalyst. Some see earlier durability and safety results as encouraging, while others are frustrated that positive developments have not translated into sustained strength in the shares.

TRON is a decentralized blockchain-based operating system designed to accelerate the decentralization of the internet and its underlying infrastructure. It serves as a global settlement layer for stablecoins and everyday digital purchases, providing a high-throughput environment to support large-scale decentralized applications. The network is governed by a decentralized autonomous organization (DAO), which allows the community to manage the protocol without a central authority. Its primary value proposition includes a unique resource model that utilizes bandwidth and energy to allow for high transaction volumes without traditional fee spikes.  The platform functions as a smart contract platform that enables the creation of decentralized applications and is compatible with the Ethereum Virtual Machine, allowing developers to easily migrate applications. TRON operates using a Delegated Proof of Stake consensus mechanism where token holders vote for 27 Super Representatives to verify transactions and maintain the ledger. This structure is built for scalability and fast finality, aiming to handle more transactions per second than many established legacy blockchains. Users can interact with the ecosystem for various purposes, including decentralized finance (DeFi) through platforms like JustLend DAO and decentralized storage via the BitTorrent File System.  Value moves through the system via its native utility token, TRX, which facilitates transactions and grants users access to network resources. Holders can lock their TRX in a staking mechanism to gain TRON Power, which is used to vote on network rules and elect Super Representatives, earning rewards for securing the network. Established by the TRON Foundation and led by founder Justin Sun, the project has transitioned into a community-led DAO. The ecosystem is supported by strategic partnerships with major global entities, including Samsung, which integrated TRON into its blockchain keystore, as well as BitTorrent, Opera, and Swisscom Blockchain.

Tron

TRON is drawing attention for range-bound trading and perceived resilience, with traders sharing technical setups and debating whether the consolidation will lead to another move higher or persist as a sluggish sideways market. Some also point to stablecoin activity and network use as supportive context, while others remain frustrated by the tokens limited movement.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Unconfirmed takeover speculation, particularly reported interest from Lundbeck, is driving much of the discussion; traders debate whether a deal is plausible after Xeris reportedly said it is not for sale. Others focus on Recorlevs growth and XP-8121s planned Phase 3 progress as reasons to value the company on its own.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Interactive Brokers Q3 results are driving discussion, with traders weighing strong profit, interest income and account growth against slower customer trading activity. The reaction is mixed: some see the higher dividend and solid fundamentals as supportive, while others are disappointed by the stocks weak post-earnings action and cite competition and valuation concerns.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines quarterly results and weaker outlook are the main focus: traders are weighing strong revenue against projected losses as elevated jet-fuel costs squeeze margins. Bearish posts cite fuel exposure and debt, while bulls point to resilient travel demand and argue that easing fuel costs could improve profitability.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is under pressure as traders cite weakness in crypto and AI/data-center stocks, with added concern about CoreWeaves role as a Helios tenant ahead of earnings. Some see the selloff as oversold and are buying the dip, while others fear disappointing results or unresolved tenant uncertainty; talk of new-tenant news remains speculation.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak quarterly results, sharply reduced full-year outlook, and dividend suspension are driving attention, with management pointing to recession-level appliance demand and the Iran war. Traders largely fear further declines amid debt and management concerns, while some see the selloff as a buying opportunity or expect a bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod 

Equity

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.


Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study

AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.

SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

Here's Why You Should Add ACET Stock to Your Portfolio Now

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.

Are Medical Stocks Lagging  Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Bearish Sentiment

<ul class="summary-bullets"><li>Ipsen’s Somatuline Depot booked $983 million in U.S. sales in the year through July, according to IQVIA.&nbsp;</li><li>The agency also granted Competitive Generic Therapy status, a label meant to speed copies of drugs that still face thin competition.</li><li>For Amneal, the launch is another hard-to-make injectable in its Affordable Medicines lineup.</li></ul><p><br>Shares of Amneal Pharmaceuticals (AMRX) extended their gains after the closing bell on Friday after the company said the U.S. Food and Drug Administration (FDA) had approved its lanreotide injection and that the product would go on sale immediately.</p><p>The stock closed at $18.71, up 2.35% in regular trading, then rose another 2% after-hours to $19.17 as investors reacted to the long-awaited launch in a market worth almost $1 billion.</p><h2 class="st-heading-2">Green Light, Then An Immediate Start</h2><p>The FDA cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection. Doctors use it to tame excess growth hormone in acromegaly, slow certain gut and pancreatic neuroendocrine tumors, and ease carcinoid syndrome flare-ups. The agency also granted Competitive Generic Therapy status, a label meant to speed copies of drugs that still face thin competition. Amneal said the product is ready now. Ipsen’s brand booked $983 million in U.S. sales in the year through July, according to IQVIA.</p><p>Rivals are already on the market, such as one made by Cipla’s InvaGen unit.</p><h2 class="st-heading-2">A Date The Company Had Been Circling</h2><p>This was not a sudden win. Amneal’s public pipeline had pointed to a third-quarter 2026 decision. On the July earnings call, co-CEO Chirag Patel said the file had a formal goal date in the quarter and that some sales were already in the forecast, though conservatively.</p><p>For Amneal, the launch is another hard-to-make injectable in its Affordable Medicines lineup, made in company plants rather than farmed out. Srinivas Kone, the unit’s chief scientific officer, said the company can supply the market at scale and use the product as a growth engine.</p><h2 class="st-heading-2">How Did AMRX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AMRX stock stayed in ‘bearish’ territory over the past 24 hours, while message volume remained ‘high.’</p><p><a href="https://stocktwits.com/symbol/AMRX">AMRX stock</a> has risen 48% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/boeing-starliner-may-get-a-bigger-nasa-role-despite-leaving-crew-behind-as-space-x-looks-past-dragon-says-report/cZtHIQ2RBEf">Boeing Starliner May Get a Bigger NASA Role Despite Leaving Crew Behind As SpaceX Looks Past Dragon, Says Report</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Amneal Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.

AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod

iShares Core S&P Small-Cap ETF

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$AMRX 
 
Amneal got FDA approval September 18 for generic lanreotide, 120 mg/0.5 mL in a prefilled syringe, referencing Ipsen's Somatuline Depot. It launched the same week. 
 
The brand did 983 million dollars in US sales over the 12 months through July, per IQVIA. 
 
The detail that matters: the approval carries Competitive Generic Therapy designation. That is the FDA's flag for drugs facing inadequate generic competition. 
 
Indications are acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. Amneal says it adds a material growth driver to its Affordable Medicines business, made on its own manufacturing lines. 
 
A complex injectable in a roughly billion-dollar market is a different kind of generic launch than a pill. In-house capacity is how it holds the share it wins.

Krypton Research

$AMRX Under accumulation. Strong Volume with increasing price.  Looking for the next leg up from here. GLTA!

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMRX Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Fundamentals

Latest AMRX News